Navigation Links
Renaissance Health Publishing, LLC Warns the Public that ConsumerLab.com is Not Independent and Labels the 'CL Seal of Approval' a Worthless, Paid-For Advertising Gimmick
Date:1/24/2008

Renaissance Health has repeatedly asked that ConsumerLab.com open their records for inspection.

"ConsumerLab.com should have to show how many companies and individuals have submitted products under its voluntary review program for a CL Seal of Approval-and paid the $3,000 to $4,000 they charge-and see how many of these products did and didn't eventually pass," says DiGeorgia.

"ConsumerLab.com tested our old formulation of Revatrol that hasn't been available for more than nine months. What reputable testing agency would test such an old, out-of-date product, without double-checking to ensure they're testing the current product?" asks an exasperated DiGeorgia.

When ConsumerLab.com was made aware of the fact that they tested a discontinued formulation, they asked Renaissance Health to pay a sizeable fee to test the current product.

"They had the audacity to ask us to pay $3,000 to $4,000 to test the current formulation - the very formulation they should have tested from the start; the formulation that had been on the market for more than nine months at the time of their testing.

"We had the current formulation of Revatrol recently tested by a commercial laboratory not affiliated with our manufacturer. And we quickly discovered that not only does our formulation include everything claimed on the label and in the advertising, but we give our customers much more of the Trans-Resveratrol, Resveratrol, Alpha Lipoic Acid, Acetyl-L-Carnitine and Quercetin than what's promised.

"Best of all our formulation gives our customers a 95% OPC. Thus, despite the fact that our product has more of everything we claim and is by far the most complete formulation, Revatrol won't ever receive a 'CL Seal of Approval' because we won't pay," says DiGeorgia.

Renaissance Health also says that claims of independence by ConsumerLab.com are compromised by its revenue model.

"I believe that any company that both charges consumers for it
'/>"/>

SOURCE Renaissance Health Publishing, LLC
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Renaissance Health Publishing, LLC Asks Key Credibility Questions of ConsumerLab.com
2. ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing
3. Gentiva(R) Health Services Promotes Boelsen to Senior Vice President, CareCentrix(R)
4. Avamere Health Systems Announces New President of Signature Home Health
5. Controlling health destiny
6. The Health Trust Announces $30 Million Investment Towards Making Silicon Valley Healthiest Region in America
7. Healthcare Workers Skeptical of Planning Process for St. Lukes
8. From Research to Practice: Healthfitness, Eastman Chemical Company Case Study Demonstrates Real-World Health Gains and Productivity Savings
9. AMA on the State of Health Care in Advance of the Presidential State of the Union Address
10. Boston Research Summit gathers 100 health care leaders on decision making
11. Accuro Healthcare Solutions, Inc. Files Registration Statement for Proposed Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 According to the National Institutes ... toxic epidermal necrolysis (TEN) that affects the skin and mucous ... adults under the age of 30 (i). In the ... and fever. As SJS advances, it affects the mucous ... and anus. Inflammation of the eye causes conjunctivitis (pink ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- The number ... units after spending time in an emergency room ... new research. The study, conducted by researchers ... Health and Health Services in Washington, D.C., found ... room on average before being admitted to the ...
(Date:5/24/2013)... new investigational device - the Helio System (TF-FA) - ... Heart Valve was successfully deployed in all four patients ... in high-risk aortic insufficiency reported at EuroPCR 2013. , ... help stabilise the SAPIEN XT valve for patients with ... captured between the transcatheter heart valve and the dock. ...
(Date:5/24/2013)... May 24, 2013 The producers of ... dates for Charlotte, North Carolina. It is one of the ... 500 companies. The city is populated with more than a ... cover residents in both North and South Carolina. Viewers who ... medically-related can tune into WAXN-TV 64 Eyewitness News during the ...
(Date:5/24/2013)... NY (PRWEB) May 24, 2013 The ... is happy to announce that it has donated $10,000 to ... the women held captive in Cleveland, Ohio. , “When the ... Jesus, Michelle Knight, and Amanda Berry and her daughter had ... a decade, we were shocked and horrified,” said Integrative Nutrition ...
Breaking Medicine News(10 mins):Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 2Health News:Personal Injury Law Firm Issues New Infographic Detailing a Potential Link Between Stevens Johnson Syndrome and Common Children’s Medicines 3Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Feasibility trial reports deployment of new device for TAVI in aortic insufficiency 2Health News:Health Briefs TV Presents May Air Dates for Charlotte, North Carolina 2Health News:Integrative Nutrition Donates $10,000 to the Cleveland Courage Fund 2
... CHAPEL HILL, N.C., May 27 As the ... companies are looking,for ways to up-sell and cross-sell ... the need for such practices, Best Practices LLC ... from less than 5% of their,service calls., ...
... NY/LOS ANGELES, CA: Stand Up To Cancer ... philanthropic dollars for accelerating ground-breaking research, launches today ... networks, entertainment industry executives, celebrities and prominent leaders ... CBS and NBC will donate one hour of ...
... TUCSON, Ariz., May 27 Medipacs, Inc., a ... is has secured an,initial financial investment of $1.65 ... Venture Partners and other investors in Tucson, San,Diego, ... Mark McWilliams comments: "We are very pleased with,the ...
... IMTEC Corporation proudly,introduces a newly redesigned version ... works in conjunction with IMTEC,s proprietary,FlashCT(R) software for ... scanner, Vision provides users with tools for viewing, ... may be in the form of,a raw scan ...
... in Melanoma , Mutations in the p14ARF tumor ... independent of the effect of the p16 gene. , ... on chromosome 9 that is frequently mutated in melanomas. ... p16 tumor suppressor gene occurs frequently in melanomas, it ...
... days off, poor-quality output, study finds , , TUESDAY, May ... hyperactivity disorder (ADHD) miss, on average, more than three ... new global reckoning of the problem. , Altogether, between ... ADHD, according to survey data from the World Health ...
Cached Medicine News:Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 2Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 3Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 4Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 5Health News:ABC, CBS, NBC announce historic collaboration to 'stand up to cancer' 6Health News:IMTEC Introduces New Vision Software 2Health News:Also in the May 27 JNCI 2Health News:Also in the May 27 JNCI 3Health News:Also in the May 27 JNCI 4Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 2Health News:Adults With ADHD Lose 3 Weeks Worth of Work Annually 3
(Date:5/24/2013)... and BOSTON , May 24, 2013 /PRNewswire/ ... development company, is pleased to announce that it has engaged Mr ... the Company,s business development capabilities in Japan ... 15 years of experience in business development, licensing and alliance management ... Roche Pharma ( Japan ), Nippon Roche and Tanabe ...
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... May 23, 2013  Haemonetics Corporation (NYSE: HAE ... CFO & EVP-Business Development, will present at The Deutsche Bank ... Boston, MA on May 29, 2013 at ... ) The public may access Mr. Lindop,s presentation ... About Haemonetics Haemonetics (NYSE: HAE ) ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... 21, 2010 /PRNewswire-FirstCall/ – ERT (Nasdaq: ERES ... the pharmaceutical, biotechnology and medical device industries, today confirmed ... of Dr. Michael J. McKelvey, its President and CEO, ... currently ERT,s Chairman and Chief Scientific Officer, has also ...
... 21, 2010 PTC Therapeutics, Inc. announced today that ... trial of ataluren, an investigational new drug, in patients ... http://photos.prnewswire.com/prnh/20010919/PTCLOGO) The 48-week study is designed to ... with nmCF.  The trial has enrolled 238 patients at ...
Cached Medicine Technology:ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO 2ERT Announces the Appointment of Joel Morganroth, MD as Interim CEO 3PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 2PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 3PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis 4
The BD Ultra-Fine 33 Lancets are the thinnest lancets available, which means that you'll experience less pain when taking a blood sample....
... blood flow and minimize pain when ... safety-engineered BD Microtainer Quikheel Lancet. The ... blade providing a precise and consistent ... into its casing, helping to protect ...
The HEMOCHRON Signature Elite offers state-of-the-art features like barcode scanning, internal Electronic Quality Control (EQC), QC Lockout and alphanumeric data entry for Patient Identification (PID...
... Our highest throughput solution for ELISA testing. ... 2 Sample Processors, 1 Robot, and 1 ... solution automatically performs: dispensing of samples from ... plate transport via the robotic transport system ...
Medicine Products: